GE HealthCare reports Q1 2026 financial results
Revenue grows 7.4% to $5.1 billion with organic growth of 2.9%. Adjusted EPS is $0.99. Reaffirms topline guidance but reduces profit outlook due to inflation. Completes Intelerad acquisition.
See the latest news and media coverage for GE HealthCare. We track all announcements, press releases, and industry mentions in real time, all in one place.
Healthcare technology and services company
gehealthcare.comLast updated
In short: GE HealthCare secured several FDA clearances for AI software and imaging tools, but lowered its profit outlook due to inflationary pressures.
Revenue grows 7.4% to $5.1 billion with organic growth of 2.9%. Adjusted EPS is $0.99. Reaffirms topline guidance but reduces profit outlook due to inflation. Completes Intelerad acquisition.
Appoints Phil Rackliffe as President and CEO of new Advanced Imaging Solutions segment and Catherine Estrampes as Chief Commercial and Growth Officer for Global Markets. Roland Rott departs.
Cardiology Associates in Mobile, Alabama, continues its legacy of innovation in coronary CTA imaging after over 20 years.
The trial tests mangaciclanol, a manganese-based MRI contrast agent under FDA Fast Track, potentially replacing gadolinium-based agents.
In early June 2026, GE HealthCare received FDA 510(k) clearance for its AI-enabled MIM Contour ProtégéAI+ 2.0 auto-contouring software, while also showcasing an expanded portfolio...
Detailed price information for GE Healthcare Technologies (GEHC-Q) from The Globe and Mail including charting and trades.
Some investors may be wondering whether GE HealthCare Technologies at around US$63.81 is starting to look like value, or if the stock still has work...
GE HealthCare GEHC recently announced that the FDA has granted 510(k) clearance for MIM Contour...
Track GE HealthCare and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to GE HealthCare and other trending companies.